The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Updates in MPNs from ASCO 2024: combination therapies, trial endpoints & future directions
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses recent advancements in Phase III studies and combination therapies involving novel agents for myeloproliferative neoplasms (MPNs). She mentions the combination of pelabresib with ruxolitinib and selinexor with ruxolitinib. Dr Masarova highlights ongoing discussions about relevant endpoints, as well as the importance of mechanistic data and future research directions. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
